Nationwide HPV campaign targets cervical cancer

A free single-dose HPV vaccination drive for 14-year-old girls, India's first universal public-health push against cervical cancer.

What happened

• The Ministry of Health and Family Welfare gave Parliament an update on the National HPV Vaccination Campaign, the country's first nationwide public-sector drive to immunise adolescent girls against the human papillomavirus (HPV) that causes most cervical cancers.
• The campaign was launched on 28 February 2026 and is administered across all 36 States and Union Territories, reaching rural and underserved areas alongside cities.
• It targets roughly 1.2 crore eligible girls aged 14 years — a single age cohort vaccinated in one coordinated push rather than an open-age roll-out.
• The vaccine used is the single-dose Gardasil-4 (a quadrivalent HPV vaccine), given free of cost at government health facilities.
• Delivery sites include Ayushman Arogya Mandirs, Primary Health Centres (PHCs), Community Health Centres (CHCs), Sub-District and District Hospitals, and Government Medical Colleges.
• After the three-month campaign window, the vaccine continues to be offered on routine immunisation days, folding it into the regular schedule rather than ending with the drive.
• Every vaccination site is linked to a 24x7 AEFI (Adverse Events Following Immunization) Management Centre, and the programme is explicitly voluntary with mandatory parental consent.
• The update was placed on record by the Minister of State for Health in Parliament; a companion PIB backgrounder notes the campaign was flagged off from Ajmer, Rajasthan.

Background & context

Cervical cancer is among the most common cancers affecting Indian women and is one of the few major cancers that is almost entirely preventable through a combination of vaccination and screening. The disease is caused by persistent infection with certain high-risk types of the human papillomavirus, a sexually transmitted virus. Because the immune response to the vaccine is strongest before exposure, public-health programmes worldwide target adolescents before the typical age of first exposure — which is exactly why this campaign fixes on the 14-year cohort rather than adult women.

India's vaccine delivery rides on the architecture of the Universal Immunization Programme (UIP), one of the largest public-health programmes in the world, run by the Ministry of Health and Family Welfare. The UIP already provides free vaccines against a panel of vaccine-preventable diseases through fixed routine-immunisation sessions at PHCs, CHCs and sub-centres, supported by the Mission Indradhanush drives that chase unvaccinated and partially vaccinated children. The HPV campaign extends this machinery to a new disease target and a new (adolescent) age group, and the decision to continue the vaccine on routine immunisation days after the three-month drive signals an intent to make HPV a standing part of the immunisation schedule rather than a one-time event.

Until this campaign, HPV vaccination in India was largely confined to the private market, a handful of State-level pilots (notably an earlier Sikkim school-based programme) and out-of-pocket purchases — which kept coverage low and unequal. A domestically manufactured quadrivalent HPV vaccine, CERVAVAC, was developed in India and rolled out to widen affordable supply; the move to a free, government-delivered, single-dose campaign is the policy step that converts availability into population-scale coverage. The single-dose schedule itself reflects an evolving global evidence base — the World Health Organization's expert advisory group has endorsed a single-dose option for the relevant age groups, which sharply cuts the logistics, cost and drop-out problems of a multi-dose regimen.

The campaign also sits inside the government's broader, three-pronged strategy against cervical cancer: vaccination (primary prevention), screening (for example HPV-DNA or visual-inspection-based screening of adult women under the population-based screening initiative run through Ayushman Arogya Mandirs / Health and Wellness Centres), and early diagnosis and timely treatment at tertiary facilities. The vaccine attacks the cause before it takes hold; screening catches pre-cancerous changes in women already past the vaccination age. The two are complementary, not substitutes — a point worth holding because exam framings often test whether a candidate treats vaccination as a replacement for screening.

It helps to place the campaign against the global benchmark. The World Health Organization has set a global elimination target for cervical cancer built on three numbers commonly summarised as 90–70–90: that 90% of girls be fully vaccinated against HPV by age 15, that 70% of women be screened with a high-performance test, and that 90% of women with disease receive treatment. Read against that ladder, India's free single-cohort drive is the country's bid to move the first of those three numbers — vaccination coverage of adolescent girls — at population scale, while the screening and treatment prongs carry the other two. Several countries that introduced public HPV vaccination years earlier have already recorded steep falls in pre-cancerous lesions among the first vaccinated cohorts, which is the kind of downstream effect this programme is designed to reproduce over a generation. The Indian design choices — a single dose, free delivery, an existing immunisation backbone, and a consent-based opt-in — are calibrated to clear the coverage bar without the cost and drop-out penalties that a multi-dose, fee-charging model would impose.

A note on how the safety chain actually works, since it is the part most likely to be tested as a discrete fact: AEFI stands for Adverse Events Following Immunization, meaning any untoward medical occurrence after a vaccine that may or may not be causally linked to it. India runs a structured AEFI surveillance system that reports and investigates such events through district and State committees up to a national level; in this campaign every vaccination site is tied to a 24x7 AEFI Management Centre so that any reaction can be managed and recorded immediately. This is the operational reason a candidate should not conflate “an adverse event after vaccination” with “a vaccine side-effect” — the surveillance system exists precisely to distinguish coincidental events from causally linked ones, and that distinction is a frequent prelims trap.

For Prelims

• Name: National HPV Vaccination Campaign — a nationwide free immunisation drive against human papillomavirus to prevent cervical cancer.
• Nodal ministry: Ministry of Health and Family Welfare, delivered through the Universal Immunization Programme's existing facility network.
• Launched: 28 February 2026; flagged off from Ajmer, Rajasthan.
• Target cohort: ~1.2 crore girls aged 14 years (a single-age cohort), across all 36 States and Union Territories, including rural and underserved areas.
• Vaccine: single-dose Gardasil-4, a quadrivalent HPV vaccine, given free at government facilities.
• Delivery sites: Ayushman Arogya Mandirs, PHCs, CHCs, Sub-District/District Hospitals and Government Medical Colleges.
• Duration & continuity: a 3-month campaign; thereafter the vaccine continues on routine immunisation days.
• Safety architecture: all sites linked to 24x7 AEFI (Adverse Events Following Immunization) Management Centres.
• Nature: voluntary; parental consent is mandatory before administration.
• Strategy set it belongs to: one of three prongs of the cervical-cancer plan — (1) vaccination, (2) screening, (3) early diagnosis and timely treatment.
• What it is NOT: it is not a multi-dose schedule (this campaign uses a single dose); it is not compulsory (it is voluntary, consent-based); it is not for all ages or for boys in this drive (the cohort is 14-year-old girls); and the vaccine does not replace cervical screening for older women — vaccination and screening are complementary. It is also distinct from the indigenous CERVAVAC vaccine: CERVAVAC is a made-in-India quadrivalent HPV vaccine, whereas Gardasil-4 is the vaccine named in this particular campaign update.

Why it matters

Cervical cancer is a heavy and avoidable burden on Indian women, and it falls hardest on those with the least access to screening and treatment. By delivering the vaccine free through the public system and explicitly reaching rural and underserved areas, the campaign tackles the equity gap that a private-market-only model leaves wide open — a girl's protection no longer depends on her family's ability to pay. The choice of a single dose is the operational pivot that makes population scale feasible: one contact point per child means lower cost, simpler cold-chain logistics, and far fewer drop-outs than a two- or three-dose schedule would produce.

Targeting a single 14-year cohort is a deliberate epidemiological design — vaccinating adolescents before likely exposure maximises the protective effect per rupee spent. Folding the vaccine into routine immunisation days after the drive means today's 14-year-olds will be followed by next year's, building durable cohort protection over time rather than a one-off spike. The 24x7 AEFI Management Centres and the voluntary, consent-based design address the trust dimension: large adolescent-vaccination programmes elsewhere have stumbled on safety scares and consent controversies, so a visible adverse-event-monitoring backbone and explicit parental consent are as much about maintaining public confidence as about clinical safety. Read against the Sustainable Development Goal of reducing premature mortality from non-communicable diseases and the WHO's global call to eliminate cervical cancer as a public-health problem, this campaign is India's most concrete step yet on the primary-prevention leg of that goal.

For Mains